Adoptive transfer of tumor-reactive CD8+ T lymphocytes is one of the most effective immunotherapy approaches for the treatment of solid tumors.1 Muranski and colleagues show that a recently identified population of CD4+ T lymphocytes called Th17 cells possesses unexpected antimyeloma therapeutic properties.

Th17 and cancer: friends or foes?

Bronte, Vincenzo
2008-01-01

Abstract

Adoptive transfer of tumor-reactive CD8+ T lymphocytes is one of the most effective immunotherapy approaches for the treatment of solid tumors.1 Muranski and colleagues show that a recently identified population of CD4+ T lymphocytes called Th17 cells possesses unexpected antimyeloma therapeutic properties.
2008
T lymphocyte; cytokine; cancer
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/347677
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 30
social impact